A molecular system controlled by a protein called FBP1 is responsible for how liver cells damaged by MASH — fully, metabolic dysfunction-associated steatohepatitis, a severe…
Fatty liver disease
FATTY LIVER DISEASE
NewsDistinct subtypes of MASLD discovered independently
An international team of researchers using different experimental approaches identified two distinct types of metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty…
FATTY LIVER DISEASE
NewsPoor sleep patterns evident in people with MASLD, MASH: Study
Troubled sleep is more common in people with metabolic dysfunction-associated steatotic liver disease (MASLD), a type of fatty liver disease, than in age-matched adults…
FATTY LIVER DISEASE
NewsNew names given nonalcoholic fatty liver diseases fit children: Study
Almost every child and adolescent who met diagnostic criteria for forms of nonalcoholic fatty liver disease under their previous names — NAFL, NASH, or…
FATTY LIVER DISEASE
NewsSemaglutide shows liver benefits in Phase 3 MASH trial
Weekly injections of semaglutide, a medication sold in the U.S. under brand names including Ozempic and Wegovy to treat type 2 diabetes and obesity, reduced…
FATTY LIVER DISEASE
NewsFatty liver disease affects 45% of teens, adults in US, Hispanics most
About 45% of teens and adults in the U.S. have some form of fatty liver disease, with Hispanic populations being more affected than other…
FATTY LIVER DISEASE
NewsSagimet planning Phase 3 trials of denifanstat in MASH, MASLD
Sagimet Biosciences is planning the launch of two Phase 3 clinical trials to test its oral therapy candidate denifanstat in people with fatty…
FATTY LIVER DISEASE
NewsStudy fully enrolled of Rezdiffra for well-compensated liver cirrhosis
A Phase 3 clinical trial testing Rezdiffra (resmetirom) in people with well-compensated cirrhosis, or irreversible liver scarring that still allows the liver to work, due…
FATTY LIVER DISEASE
NewsTherapy to silence SPTBN1 protein eases liver fat, scarring in mice
Suppressing the production of the SPTBN1 protein reduces liver fat, inflammation, and scarring (fibrosis) in mouse and human models of two forms of fatty…
FATTY LIVER DISEASE
NewsSurvodutide wins breakthrough therapy for fatty liver disease
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy status to survodutide, an experimental injectable therapy by Boehringer Ingelheim for metabolic dysfunction-associated steatohepatitis…
Recent Posts
- One of my superpowers for MASH is defiance in the name of compliance
- Canada approves Livmarli oral tablets for Alagille itching
- New experimental therapy enters early human testing for hepatitis B
- Risk of PSC recurrence 4 times higher with living donor transplant: Study
- Early detection highlighted in this year’s Rare Liver Diseases Month